Showing 2491-2500 of 6036 results for "".
- Kiora Pharmaceuticals Presents In Data Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathyhttps://modernod.com/news/kiora-pharmaceuticals-presents-in-data-demonstrating-the-potential-of-kio-104-to-treat-proliferative-vitreoretinopathy/2482784/Kiora Pharmaceuticals announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The presentation, titled, "KIO-104, a novel small molecule inhibitor o
- 4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DMEhttps://modernod.com/news/4dmt-announces-rmat-designation-granted-by-fda-for-4d-150-for-dme/2482776/4D Molecular Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME). RMAT designation is part of the 21st Century Cures Act and was created to expedite the developmen
- RetinAI and FVS Announce CE-MDR Certification for Co-Developed AI-Based DR Screening Algorithm, LuxIAhttps://modernod.com/news/retinai-and-fvs-announce-ce-mdr-certification-for-co-developed-ai-based-dr-screening-algorithm-luxia/2482773/RetinAI US and Fundación Ver Salud (FVS) have jointly announced that LuxIA, their co-developed AI algorithm for diabetic retinopathy (DR) screening, has successfully received CE-MDR certification as a Class IIb medical device under the European
- SpyGlass Pharma Presents 18-Month Data Demonstrating Improvements in Visual Acuity with IOL-Mounted Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-presents-18-month-data-demonstrating-improvements-in-visual-acuity-with-iol-mounted-drug-delivery-platform/2482772/SpyGlass Pharma announced that 18-month data from the first-in-human study of the SpyGlass Drug Delivery Platform demonstrated improvements in both visual acuity and IOP outcomes, key objectives for long-term treatment of glaucoma or ocular hypertension. Th
- Azalea Vision Raises €9 Million to Further Develop Intelligent Connected Vision Platformhttps://modernod.com/news/azalea-vision-raises-eur9-million-to-further-develop-intelligent-connected-vision-platform/2482765/Startup biotech company Azalea Vision announced the first closing of its €15 million Series A funding round, raising €9 million. In addition, the company announced that Robert J. Dempsey has been appointed Chairman of the Board to guide strategic growth in the European an
- Aurion Makes Leadership Announcementshttps://modernod.com/news/aurion-makes-leadership-announcements/2482757/Aurion Biotech announced the appointments of Edward J. Holland, MD, as Chief Medical Officer, and Eris P. Jordan, OD, as Chief Development Officer. Aurion is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema seconda
- FDA Denies Regeneron's BLA for Extended Dosing Intervals for Eylea HDhttps://modernod.com/news/fda-denies-regenerons-bla-for-extended-dosing-intervals-for-eylea-hd/2482747/Regeneron announced that the FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved indication
- Pantheon Vision Announces Partnership with EyeDeal Medical to Develop Bioengineered Corneal Implanthttps://modernod.com/news/pantheon-vision-announces-partnership-with-eyedeal-medical-to-develop-bioengineered-corneal-implant/2482719/Pantheon Vision today announced a partnership with manufacturer EyeDeal Medical to develop an artificial, bioengineered corneal implant. Their goal, the company states, is to eliminate corneal blindness by removing the need for human donor corneal tissue. Corneal blindness is the
- Staar Surgical Announces Restructure of Leadershiphttps://modernod.com/news/staar-surgical-announces-restructure-of-leadership/2482705/Staar Surgical announced a series of changes to their leadership structure. These changes come in an effort to better address marketing needs, according to Staar. Warren Foust, Chief Operating Officer, has been promoted to the newly created role of Preside
- Harrow Secures 5-Year Strategic Agreement for Triesence and Announces Next-Generation Developmenthttps://modernod.com/news/harrow-secures-5-year-strategic-agreement-for-triesence-and-announces-next-generation-development/2482696/Harrow announced the execution of a 5-year strategic supply and development (SSD) agreement for Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL. This preservative-free synthetic corticosteroid is FDA-approved for visualization during vitrectomy